The latest sales price of Sotorasib in 2024 is announced! How much cheaper are generic drugs than original drugs?

Sotorasib is an innovative anti-cancer drug mainly used to treat KRAS G12C mutated non-small cell lung cancer (NSCLC). KRAS G12CMutation is a common cancer-related genetic mutation that is widespread in many cancers, especially in patients with non-small cell lung cancer. The development of sotorasiib aims to intervene in this specific genetic mutation in a targeted manner and provide patients with a precise treatment plan.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

Its mechanism of action is mainly by inhibiting the activity of KRAS G12C mutant, blocking abnormal signaling pathways in cancer cells. KRAS G12CThe mutation drives the growth, division, and spread of cancer cells, and the inhibitory effect of sotoracib helps slow or even stop these abnormal processes, thereby hindering tumor development. This precise targeted treatment mechanism is more targeted than traditional chemotherapy drugs and is expected to minimize damage to normal cells and improve the safety of treatment.

Clinical trials of sotoraxib have shown some encouraging results. For patients with KRAS G12C mutant non-small cell lung cancer, some patients have significantly inhibited tumor growth and even experienced tumor shrinkage after receiving sotoraxib treatment. This provides new treatment options for patients who have previously had limited response to traditional treatments.